# Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

> **NCT00107653** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 569 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT00107653
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 569 (ACTUAL)
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107653, "Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00107653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*